Free Trial
OTCMKTS:CURLF

Curaleaf Q1 2025 Earnings Results & Report

Curaleaf logo
$8.81 -0.12 (-1.34%)
As of 02:02 PM Eastern

Curaleaf met analyst earnings expectations in its Q1 2025 results, released May 8, 2025. The company reported EPS of -$0.21 versus the -$0.21 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
After Market Closes

Curaleaf EPS Results

Actual EPS
-$0.21
Consensus EPS
-$0.21
Beat/Miss
Met Expectations
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

Curaleaf Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Curaleaf Q1 2025 Earnings FAQ

Curaleaf (OTCMKTS:CURLF) reported earnings of -$0.21 per share for Q1 2025, matching the consensus estimate of -$0.21. The report was announced on Thursday, May 8, 2025.

Curaleaf Earnings Headlines

A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel
See More Curaleaf Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Curaleaf? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Curaleaf and other key companies, straight to your email.

About Curaleaf

Curaleaf (OTCMKTS:CURLF) is a cannabis company that cultivates, processes and sells cannabis products for medical and adult-use markets. Its products include cannabis flower, pre-rolls, concentrates, vapes, edibles, tinctures and topical products, sold under brands including Curaleaf, Select and Grassroots.

The company operates across multiple U.S. markets through cultivation and processing facilities, wholesale operations and retail dispensaries. Through Curaleaf International, it also serves medical cannabis markets in Europe and other international markets.

Curaleaf traces its origins to 2010 and adopted the Curaleaf name in 2018. Boris Jordan is the company’s executive chairman, and Matt Darin serves as chief executive officer.

View Curaleaf Profile